Purpose: Ageing is the strongest predictor of neovascular age-related macular degeneration (AMD), where neuroinflammation is known to play a major role. Less is known about polypoidal choroidal vasculopathy (PCV), which is an important differential diagnosis to neovascular AMD. Here, we report plasma markers of inflammation with age (inflammaging) in patients with PCV, patients with neovascular AMD and a healthy age-matched control group. Methods: We isolated plasma from fresh venous blood obtained from participants (n = 90) with either PCV, neovascular AMD, or healthy maculae. Interleukin(IL)-1b, IL-6, IL-8, IL-10 and tumour necrosis factor receptor 2 (TNF-R2) were measured using U-PLEX Human Assays. Routine plasma Creactive protein (CRP) was measured using Dimension Vista 1500. Results: Patients with PCV had plasma levels of IL-1b, IL-6, IL-8, IL-10 and TNF-R2 similar to that in healthy controls. Patients with neovascular AMD had significantly higher plasma IL-1b, IL-6 and IL-10 than healthy controls, whereas no significant differences were observed for plasma IL-8 and TNF-R2. Differences between plasma IL-1b, IL-6 and IL-10 possessed a positive but weak ability in discriminating neovascular AMD from PCV. Both patients with PCV and patients with neovascular AMD had significantly higher levels of routine plasma CRP. Conclusion: Patients with PCV differ from patients with neovascular AMD in terms of plasma inflammaging profile. Apart from increased CRP, no signs of inflammaging were observed in patients with PCV. In patients with neovascular AMD, we find a specific angiogenesis-twisted inflammaging profile.
Introduction
In 2000, Dr. Claudio Franceschi and colleagues coined the term Inflammaging to describe the age-related reduction in the capacity of the immune system to adequately handle immunological stress and to describe the associated general shift towards a more pro-inflammatory immune profile (Franceschi et al. 2000) . Accelerated inflammaging is a strong predictor of mortality and has been linked to the development of age-related neurodegenerative and neuroinflammatory diseases (Bruunsgaard 2006; Giunta et al. 2008) . Inflammaging-related proinflammatory shift in the systemic circulation is classically described as changes in plasma concentration of the cytokines interleukin(IL)-1b, IL-6, IL-8, IL-10, tumour necrosis factor(TNF)-a and the acute-phase reactant C-reactive protein (CRP) (Bruunsgaard 2006) . Interestingly, some of these markers of inflammaging have been implicated in age-related macular degeneration (AMD) (Kersten et al. 2018) . Early stages of AMD are clinically characterized with the formation of drusensubretinal pigment epithelium (RPE) deposits of cellular debris (Khandhadia et al. 2012) . Formation of these deposits is a result of an age-related decline in the efficacy of the retinal tissue and the RPE to handle the constant exposure of reactive oxygen species (Chen et al. 2016a,b) . Inflammaging is thought to accelerate this process (Khandhadia et al. 2012; Chen et al. 2016a,b) . One late-stage clinical manifestation of AMD is the vascular endothelial growth factor (VEGF)-induced choroidal neovascularizations (CNV).
Neovascular AMD is associated with a number of immunological alterations and inflammatory findings, including findings of systemic immunological alterations and increases in proinflammatory cytokines (Kutty et al. 2016; Kersten et al. 2018) . However, existing studies on plasma markers of inflammation in AMD rarely distinguish neovascular AMD from polypoidal choroidal vasculopathy (PCV), which is an important differential diagnosis to neovascular AMD (Laude et al. 2010; Lorentzen et al. 2017b) . Polypoidal choroidal vasculopathy (PCV) is similar to neovascular AMD in being a CNV-dominated disease that is seen in the elderly (Laude et al. 2010; Lorentzen et al. 2017b) . Unlike neovascular AMD, however, drusen formation does not precede the development of PCV (Laude et al. 2010) . Clinically, PCV has two distinct characteristics that can be seen using indocyanine green angiography (ICGA): polyp-like aneurysmal dilations of choroidal origin and a branching vascular network (BVN) (Laude et al. 2010) . Polypoidal choroidal vasculopathy (PCV) is present in a substantial number of patients with an initial diagnosis of neovascular AMD (5%-10% in Caucasians and >50% in Asians) (Laude et al. 2010; Coscas et al. 2014; Lorentzen et al. 2017b) .
It remains unclear whether PCV and neovascular AMD constitute two clinically different diseases with same or different aetiologies (Laude et al. 2010) . Although PCV is similar to neovascular AMD in being a VEGFmediated disease (Tong et al. 2006; Lee et al. 2013; Hu et al. 2016) , studies also find evidence of important aetiological differences, for example increased extracellular matrix degradation in patients with PCV and genetic mutations only present in patients with PCV (Laude et al. 2010; Zeng et al. 2013; Huang et al. 2016 ). Blood markers of inflammaging in patients with PCV are so far undescribed.
The aim of this study was to investigate markers of inflammaging in patients with PCV and patients with neovascular AMD. Unlike most existing studies, this study is distinguished using a detailed clinical protocol able to distinguish PCV from neovascular AMD to provide disease-specific insight into aspects of inflammaging. In addition, we explored markers of inflammaging in relation to pachychoroid neovasculopathy -a new clinical definition of CNV diseases associated with a thick dilated choroid wherein patients with PCV may constitute a part of the spectrum (Miyake et al. 2015; Pang & Freund 2015) .
Materials and Methods
This was a prospective observational clinic-based case-control study. All aspects follow the principles in the Declaration of Helsinki. Ethics committee approval was obtained from the Regional Committee of Ethics in Research of the Region of Zealand (jr. no. SJ-379). Participants had the nature of the study explained and oral and written informed consent was obtained prior to participation.
Previous studies and considerations for sample size
Systemic cytokine markers of inflammaging have not been reported for patients with PCV. For patients with neovascular AMD, 13 studies have investigated one or more of inflammaging-related cytokines (mostly CRP, IL-6 and TNF-a) (Klein et al. 2005 (Klein et al. , 2008 (Klein et al. , 2014 Seddon et al. 2005; Wu et al. 2007; Wang et al. 2008; Mo et al. 2010; Colak et al. 2012; Zehetner et al. 2014; Ambreen et al. 2015; Faber et al. 2015; Guymer et al. 2015; Haas et al. 2015; Nassar et al. 2015) . Kersten et al. (2018) recently summarized these findings in a systematic review. Apart from Faber et al. (2015) and Haas et al. (2015) which used ICGA for retinal diagnosis, other studies did not employ ICGA for diagnosis and some even based retinal diagnosis solely on fundus photography (Klein et al. 2005 (Klein et al. , 2008 (Klein et al. , 2014 Seddon et al. 2005; Wu et al. 2007; Wang et al. 2008; Mo et al. 2010; Colak et al. 2012; Zehetner et al. 2014; Ambreen et al. 2015; Guymer et al. 2015; Nassar et al. 2015) . Hence, the results do not allow distinguishing cases with PCV from cases with an initial diagnosis of neovascular AMD. Apart from the studies by Guymer et al. (2015) and Zehetner et al. (2014) , cytokines were measured in serum (Klein et al. 2005 (Klein et al. , 2008 (Klein et al. , 2014 Seddon et al. 2005; Wu et al. 2007; Wang et al. 2008; Mo et al. 2010; Colak et al. 2012; Ambreen et al. 2015; Faber et al. 2015; Haas et al. 2015; Nassar et al. 2015) . Concerns have been raised regarding the reliability of immunological measurements using serum samples because of platelet activation and degranulation that consequently may alter the cytokine concentrations (O'Neal et al. 2014) .
Taken together, we realized that there are actually no other comparable studies that comprehensively investigated plasma markers of inflammaging in patients with neovascular AMD that have been subject to a comprehensive retinal diagnosis that includes ICGA. We were unable to perform any meaningful power calculations. We aimed for 30 participants in each group and stopped after a total of 90 eligible samples for analyses.
Retinal diagnosis and participant eligibility
All participants underwent ophthalmologic examination by an experienced retinal specialist using slit-lamp biomicroscopy, digital fundus photography and spectral-domain optical coherence tomography (Spectralis SpectralDomain HRA-OCT, Heidelberg Engineering, Heidelberg, Germany), and retinal angiography (fluorescein and ICGA) if CNV was suspected. Based on the Clinical Age-Related Maculopathy Staging (CARMS) system (Seddon et al. 2006 ), a healthy retina was diagnosed if <10 small drusen (diameter <63 lm) with no pigment abnormalities (CARMS 1), and neovascular AMD was diagnosed in the presence of fibrovascular pigment epithelium detachments and choroidal neovascular membranes with subretinal or sub-RPE haemorrhages or fibrosis together with drusen (CARMS 5). The definition of neovascular AMD included type 1, type 2 and type 3 CNV. Eyes with PCV had one or more polyps in earlyphase ICGA with a hypofluorescent halo and with/without BVN. Other PCV stigmata were used to support the diagnosis: orange-red focal subretinal polyplike structures, pulsation of polyps on ICGA video and OCT images showing a choroidal protrusion that elevates the RPE from the Bruch's membrane (Laude et al. 2010; Lorentzen et al. 2017b ).
We performed a post hoc analysis of our patient cases, where we identified those having pachychoroid neovasculopathy as defined by Miyake et al. (2015) . Patients were defined as having pachychoroid neovasculopathy if they had all of the following requirements: angiographic presence of CNV, no drusen or the presence of drusen staged at no more than CARMS level 1 at either eye and a thick choroid defined as subfoveal thickness of >200 lm.
Participants were recruited in a consecutive manner from our retinal clinic at Department of Ophthalmology, Zealand University Hospital, Roskilde, Denmark. We recruited participants with either PCV in one or both eyes, neovascular AMD in one or both eyes, or healthy retinas in both eyes (healthy controls). Two pilot studies were conducted to better design this current study. First, we identified that lifestyle factors in patients with AMD have a significant impact on plasma CRP (Subhi et al. 2014) . Therefore, healthy controls were recruited among patients' biologically unrelated relatives aged at least 60 years to better match the control group to the patient groups. These healthy individuals were recruited when they visited our clinic while accompanying the patient. Second, we identified that a recent onset of CNV in patients with AMD is associated with systemic changes of the immune system . Because the aim of this study was to investigate chronic systemic changes, we refrained from recruiting participants with newly diagnosed neovascular AMD or PCV in either eye. Participants were invited for participation if they had no known ongoing increased or decreased immune activity or dysfunction (no active cancer, no immune disease, no ongoing or chronic infectious disease and no chemo-or immunotherapy for any reason). This strategy was employed to avoid blurring the results from other known immune diseases.
Medical interview, lifestyle factors and blood sampling
All participants were interviewed for medical history and we crosschecked medical data with patients' electronic patient journal for accuracy. We did not perform separate diagnoses of nonocular comorbidities. We specifically noted four highly prevalent and important comorbidities: hypertension, hypercholesterolaemia, any other cardiovascular disease and type 2 diabetes. Lifestyle factors were noted based on a structured interview regarding alcohol consumption, smoking habits and physical activity. Alcohol consumption was reported in units of alcohol per week (1 unit = 15 ml or 12 g of ethanol), which is a term known to layman in Denmark. Smoking habits were categorized into current smoker, previous smoker (>100 cigarettes or equivalent amount of other tobacco during lifetime, but ceased smoking >12 months) or never smoker. Physical activity was evaluated using a yes/no survey question for epidemiological studies, which is validated in elderly Danes including patients with AMDrelated visual impairment (Subhi et al. 2014; Subhi & Sørensen 2016) . In addition, height and weight were measured to calculate body mass index. Venous blood was sampled from antecubital veins in lithium heparin-coated tubes. One lithium heparin-coated tube was used for routine plasma CRP measurement using Dimension Vista Ò 1500 (Siemens Healthineers, Erlangen, Germany) that yields one of following results: <2.9 mg/l, 2.9-190 mg/l (reported in the specific concentration level) or >190 mg/l. A mild elevation in CRP (2.9 or above) is classically considered a sign of chronic inflammation and a high-risk factor for cardiovascular morbidities (Ridker & Cook 2004; Speidl et al. 2005; Graf et al. 2009 ). Other tubes with lithium heparin were left at room temperature for at least 30 min for stabilization in lithium heparin. All centrifugation and plasma isolation were completed within 4 h. Lithium heparin stabilized blood was centrifuged for 15 min at 4°C 1500 G after which plasma was isolated and stored at À80°C for later quantification of plasma cytokines. Participants with plasma CRP >15 mg/l were not included for this study to avoid including participants with an ongoing acutephase reaction or infection (Rifai & Ridker 2001 ).
Cytokine assays
We quantified plasma levels of IL-1b, IL-6, IL-8, IL-10 and TNF-R2. Instead of quantifying the labile cytokine TNFa, we quantified the soluble TNF-R2, which has a longer half-life and is a more stable measure of the average TNF-a level (Faber et al. 2015) . Cytokines were quantified using the commercially available U-PLEX Human Assays TM (U-PLEX, Meso Scale Diagnostics, Rockville, MD, USA). The assays were performed as per the manufacturer's instructors and recommendations. Each plate was first coated with coupling antibodies. Calibrators prepared using Diluent 43 TM (Meso Scale Diagnostics) were added to the first two columns so that they were run in duplicate. Remaining wells were used for our plasma samples prepared using Diluent 43 TM (Meso Scale Diagnostics), which were also run in duplicate. After sealing and incubating for 1 hour at room temperature with shaking, plates were washed three times with Phosphate Buffered Saline with Tween (PBS-T), after which detection antibodies prepared in Diluent 3 TM (Meso Scale Diagnostics) were added. After sealing and incubating for another 1 h at room temperature with shaking, plates were washed three times with PBS-T. Read Buffer TM (Meso Scale Diagnostics) was added and the plates were immediately read on QuickPlex SQ120 TM (Meso Scale Diagnostics) using electrochemiluminescence. The reader converts luminescence measures to a plasma concentration based on given calibrator concentrations. Duplicate measurements allowed samplespecific calculation of coefficient of variation (CV), which we used as a guide to reanalyse any samples with too high CV (>20%). Quality of the cytokine assays was satisfactory (CV in % mean AE SD of the individual cytokines: IL-1b: 6.4 AE 5.0; IL-6: 5.1 AE 3.8; IL-8: 3.5 AE 2.8; IL-10: 5.0 AE 4.7; TNF-R2: 9.2 AE 6.5).
Statistical analysis
All statistical analyses were made using SPSS TM v. 23 (IBM Corporation, Armonk, NY, USA). Mean and standard deviation (SD) and parametric tests were used where normal distribution was present, and otherwise median and interquartile range (IQR) and nonparametric tests were used. Categorical variables were presented in numbers and percentages and compared between groups using the chi-square test; however, Fisher's exact test when comparing groups with small categories (n ≤ 4) as the approximation of the chi-square test is considered inadequate in such cases. Significant findings were included in multivariate logistic regression analyses wherein associations were adjusted for the potential influence from covariates (demographics (age and sex), comorbidities (hypertension, cardiovascular disease, hypercholesterolaemia, type 2 diabetes) and lifestyle factors (smoking, alcohol consumption, body mass index and physical activity)). Cytokines significantly different were used for receiver operating characteristics (ROC) analyses to evaluate the discriminatory abilities of the cytokines as a biomarker (interpretation of the discriminatory abilities was based on the following rule of thumb: area under the curve (AUC) 0.5-0.6 = poor/none, 0.6-0.7 = weak, 0.7-0.8 = moderate, 0.8-0.9 = strong, 0.9-1.0 = excellent). In other words, the AUC reflects the ability for the cytokines to correctly identify predefined groups. A useless test that is no better at identify predefined groups than flipping a coin has an AUC of 0.5; whereas a perfect test will always correctly identify such predefined groups and obtain an AUC of 1.0. p-values below 0.05 were interpreted as sign of statistical significance.
Results
Participant characteristics are summarized in Table 1 . The groups only differenced significantly in the prevalence of type 2 diabetes as a comorbidity (p = 0.022, Fisher's exact test). A trend towards a difference was observed in smoking habits (p = 0.084, Fisher's exact test). Because of these differences, we wanted to investigate their possible influence on our data sample. We compared all our plasma measures between those with and without type 2 diabetes as a comorbidity and found no significant differences (p > 0.05 for all comparisons, data not shown), and also across different groups of smoking habits and found no significant differences (p > 0.05 for all comparisons, data not shown).
No significant differences between the groups were observed for IL-8 (p = 0.87, Kruskal-Wallis test) or TNF-R2 (p = 0.67, Kruskal-Wallis test) ( Table 2 ). Significant differences between the groups were observed for IL-1b (p = 0.037, Kruskal-Wallis test), IL-6 (p = 0.0010, Kruskal-Wallis test) and IL-10 (p = 0.0003, Kruskal-Wallis test). These three markers were compared in more detail (Table 2) .
Patients with PCV had lower levels of IL-1b, IL-6 and IL-10 when compared to patients with neovascular AMD. Differences reached statistical significance in IL-6 (p = 0.047, Mann-Whitney U-test) and IL-10 (p = 0.027, Mann-Whitney U-test), but not in IL-1b (0.12, Mann-Whitney U-test). Neither IL-1b (p = 0.47, MannWhitney U-test), IL-6 (p = 0.38, MannWhitney U-test), nor IL-10 (p = 0.16, Mann-Whitney U-test) differed significantly between patients with PCV and healthy controls.
Patients with neovascular AMD had significantly higher plasma levels of IL-1b (p = 0.011, Mann-Whitney Utest), IL-6 (p = 0.0001, Mann-Whitney U-test) and IL-10 (p < 0.0001, MannWhitney U-test) when compared to healthy controls. Therefore, inflammaging as a plasma biomarker may be more a neovascular AMD issue rather than PCV issue.
We further investigated IL-1b, IL-6 and IL-10 in multivariate logistic regression models to elucidate whether relationships remained after adjusting for covariates (demographics, comorbidities, lifestyle factors). Associations with neovascular AMD were confirmed All values are in pg/ml and presented in median, mean in brackets and interquartile range in parentheses. HC = healthy controls, IL = interleukin, IQR = interquartile range, nAMD = neovascular agerelated macular degeneration, PCV = polypoidal choroidal vasculopathy, TNF = tumour necrosis factor.
for IL-1b (OR = 2.50 (CI 95%: 1.41-4.47) p = 0.002), IL-6 (OR = 2.13 (CI 95%: 1.22-3.72) p = 0.008) and IL-10 (OR = 3.74 (CI 95%: 2.09-6.67) p < 0.001). No significant associations with PCV were found for IL-1b (OR = 1.13 (CI 95%: 0.63 to 2.04) p = 0.68), IL-6 (OR = 1.37 (CI 95%: 0.78-2.42) p = 0.28) and IL-10 (OR = 1.73 (OR = 0.98-3.07) p = 0.060).
To further investigate these associations and their potential usability in practice, we included IL-1b, IL-6 and IL-10 for ROC curve analyses to evaluate these markers' ability as biomarkers. We investigated discriminative abilities of IL1b, IL-6 and IL-10 in a sample of patients with CNV (neovascular AMD and PCV) (Fig. 1) . Receiver operating characteristics (ROC) curve analyses in this sample showed a weak discriminatory ability of IL-1b (AUC = 0.62, p = 0.12), IL-6 (AUC = 0.65, p = 0.047) and IL-10 (AUC = 0.67, p = 0.027). These findings suggest that inflammaging markers plasma IL-6 and IL-10 possess a positive but weak ability in distinguishing PCV from neovascular AMD. Receiver operating characteristics (ROC) curves showed no discriminative ability for PCV against healthy controls (AUC were 0.56 (p = 0.47) for IL-1b, 0.57 (p = 0.38) for IL-6 and 0.61 (p = 0.16) for IL-10). In a sample of patients with neovascular AMD and healthy controls, ROC curves showed a weak-to-moderate discriminative ability (AUC were 0.69 (p = 0.011) for IL-1b, 0.78 (p = 0.0001) for IL-6 and 0.80 (p < 0.0001). These findings suggest that inflammaging markers plasma IL1b, IL-6 and IL-10 cannot be used as a biomarker to distinguish disease vs. no disease for PCV, but do possess a positive weak-to-moderate ability in distinguishing disease vs. no disease for neovascular AMD.
Elevated levels of plasma CRP (≥2.9 mg/l) were present in 41% of patients with neovascular AMD, in 38% of patients with PCV and in 12% of the healthy controls. Plasma CRP was significantly higher in patients with neovascular AMD and patients with PCV when compared to healthy controls (p = 0.022 and p = 0.031, respectively, for neovascular AMD and PCV, v 2 test). We used a multivariate logistic regression analysis, which confirmed these associations (neovascular AMD: OR = 4.9 (CI 95%: 1.16-20.6) p = 0.030; PCV: OR = 4.6 (CI 95%: 1.02-20.5) p = 0.047) after adjusting for covariates (demographics, comorbidities, lifestyle factors).
In our post hoc analysis of those who could be classified as having pachychoroid neovasculopathy (n = 19), we found that CRP was significantly increased (p = 0.009, Fisher's exact test), but found no significant differences in IL-1b (p = 0.26, Mann-Whitney U-test), IL-6 (p = 0.60, MannWhitney U-test), IL-8 (p = 0.93, Mann-Whitney U-test), IL-10 (p = 0.20, Mann-Whitney U-test) or TNF-R2 (P = 0.27, Mann-Whitney U-test) (Table 3) .
Discussion
The classical framework of inflammaging describes that continuous antigenic load and tissue stress leads to a more chronic change in cytokine secretion from leucocytes and in particular cells of the innate immune system (Franceschi et al. 2000; Bruunsgaard 2006 ). Specifically, pathogen and danger associated molecular patterns are recognized by macrophages using pattern recognition receptors, which downstream induces the expression of IL-1b precursor (pro-IL-1b) (Lopez-Castejon & Brough 2011). Pro-IL-1b is cleaved to the active IL-1b by caspase-1 that is activated in areas of ongoing inflammation (LopezCastejon & Brough 2011 ). This process is facilitated through inflammasome activation (Guo et al. 2015) . Another early response to inflammation is through TNF-a secretion (Bruunsgaard 2006) . TNF-a binds to TNF receptors activating downstream cellular response to inflammation including the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-jB) system, which is a fast-and early-responder to cellular stress (Rothe et al. 1995; Bruunsgaard Statistical comparisons are made using Mann-Whitney U-test. All values are in pg/ml and presented in median, mean in brackets and interquartile range in parentheses. HC = healthy controls, IL = interleukin, nAMD = neovascular age-related macular degeneration, PCV = polypoidal choroidal vasculopathy, TNF = tumour necrosis factor.
2006). These early responding IL-1b and TNF-a upregulate the expression of IL-6 and IL-8 (Li et al. 2003; Bruunsgaard 2006) . The pro-inflammatory effects of IL-6 include dysfunction of the endothelium (Wassmann et al. 2004 ), propagation of oxidative damage and endothelial chemokine expression and secretion of VEGF (Cohen et al. 1996; Romano et al. 1997) . Plasma CRP is a hepatic produced acute-phase reactant through IL-1b, IL-6 and TNF-a stimulation, which therefore mirrors the overall systemic levels of pro-inflammatory cytokines (Bruunsgaard 2006) . IL-8 is a chemokine and plays an important role for endothelial proliferation, breakdown of extracellular matrix and promotion of angiogenesis (Li et al. 2003) .
To counterbalance pro-inflammatory activities, the expression and secretion of anti-inflammatory IL-10 are linked to IL-6 and TNF-a (Bruunsgaard 2006; Couper et al. 2008) . The homoeostasis between the pro-inflammatory IL-1b/ IL-6/TNF-a and the anti-inflammatory IL-10 leads to an attenuation of the activities of macrophages and T helper (Th)-1 cells so that pathogens can be cleared with minimum resident tissue damage (Couper et al. 2008) . In individuals with accelerated inflammaging, IL-1b/IL-6/TNF-a are increased and IL-10 is decreased, and this tipped balance is thought to exaggerate the immune response to continuously present tissue stress from, for example reactive oxygen species (Franceschi et al. 2000; Bruunsgaard 2006) . Possible presence of an accelerated inflammaging is therefore an important topic in agerelated neurodegeneratory and neuroinflammatory diseases (Franceschi et al. 2000; Bruunsgaard 2006; Giunta et al. 2008) .
Patients with PCV only presented with higher plasma CRP compared to healthy controls. Previous studies on plasma CRP in PCV (2 studies were identified in the literature) also suggest a possible association: Kikuchi et al. (2007) found that higher CRP was significantly associated with PCV and Cheng et al. (2014) found that an association between PCV and higher CRP but this finding did not reach statistical significance. In the aqueous humour, Sakurada et al. (2015) found elevated levels of CRP but not IL-6, IL-8 or IL-10 Sakamoto et al. (2018) found elevated levels of IL-6 and IL-10; and Hu et al. (2016) found elevated levels of TNF-a but not IL-6 or IL-8. Although we did not find any strong evidence of accelerated inflammaging in patients with PCV, our results in this study also do not exclude a possible role for immune activity in PCV. We recently reported that when cases with PCV are stratified by their angiographic subtype (strong versus weak presence of BVN (Lorentzen et al. 2017a )), we observe differences in the immunologic profile of circulating monocytes . In this study, no significant differences in plasma markers of inflammaging were found between PCV patients across angiographic subtype (data not shown). We can therefore only conclude that inflammaging-and not necessarily other immunological pathways-do not seem to play a significant role in PCV.
Pachychoroid neovasculopathy is a new clinical definition of CNV diseases associated with a thick dilated choroid and patients with PCV constitutes a significant part of the spectrum (Miyake et al. 2015; Pang & Freund 2015) . Apart from clinical considerations, very limited aetiological data are currently available for pachychoroid neovasculopathy. We find that CRP is significantly increased in patients with pachychoroid neovasculopathy, but find no other significant increase in the inflammaging markers investigated.
In patients with neovascular AMD, we find increased plasma levels of the pro-inflammatory IL-1b and IL-6, which may explain the increased plasma CRP. Kutty et al. (2016) investigated the effect of pro-inflammatory cytokines (using a cocktail of interferon gamma, TNF-a and IL-1b) on cultured ARPE-19 cells' gene expression. These pro-inflammatory cytokines induced RPE cells' expression of AMD-associated chemokines such as CCL2/MCP-1 and CXCL10/IP-10 ( Kutty et al. 2016; Kersten et al. 2018) . These findings were replicated by Natoli et al. (2017) in rat retina model underscoring their importance in vivo as well. CCL2/MCP-1 facilitates the migration and infiltration of circulating monocytes that play a key role for CNV formation upon retinal stress (Kersten et al. 2018 ). Higher systemic levels of CCL2/MCP-1 and its receptor CCR2 on monocytes have been reported in patients with AMD (Kersten et al. 2018 ). CXCL10/IP-10 is a pro-inflammatory and angiostatic chemokine (Mo et al. 2010 ), and we previously found a decreased expression of its receptor CXCR3 in patients with neovascular AMD Singh et al. 2017 ).
IL-6 plays an interesting role in relation to ageing and AMD. Katz et al. (1989) demonstrated that IL-6 stimulates complement factor B and C3 synthesis. Complement factor B and C3 is increasingly expressed with age by the RPE (Chen et al. 2008) , and Lechner et al. (2016) found increased levels of complement proteins C3a, C4a and C5a in plasma of patients with neovascular AMD. Interestingly, the presence of C3a also upregulates the synthesis of IL-6 in copresence of IL-1b (Fischer et al. 1999) . Taken together, these classical characteristics of inflammaging that are present in patients with neovascular AMD may play an important role in the disease process.
The anti-inflammatory IL-10 was increased in patients with neovascular AMD, which does not fit with the classical framework of inflammaging in which we would expect a decrease (Bruunsgaard 2006) . IL-10 receptor ligation leads to STAT3 phosphorylation (Dace et al. 2008) . STAT3 phosphorylation is increased in monocytes of patients with neovascular AMD and linked to pathologic VEGF expression in the retina Chen et al. 2016a,b) . IL-10 stimulation of CD8 + cytotoxic T cells lead to secretion of the cytotoxic granzyme B and perforin (Chan et al. 2015) , which may contribute to an understanding of why patients with neovascular AMD seem to have increased activity in subpopulations of the CD8 + cytotoxic T cells (Faber et al. 2013; Falk et al. 2014) . In addition to this, we identified a lower percentage of CD4 + Th1 cells in patients with neovascular AMD , which makes sense in the light of the IL-10 mediated attenuation of Th1 activity (Couper et al. 2008) . The concept of IL-10 as an important mediator of age-related retinal CNV has been the topic of an interesting series of studies by Dr. Rajendra Apte and colleagues (Kelly et al. 2007; Dace et al. 2008; Nakamura et al. 2015) . Retinal neovascularization response towards ischaemia was reduced in mice treated with IL-10 inhibiting antibodies as well as in IL-10 knock-out mice (Dace et al. 2008) . IL-10 mediated neovascularization involved STAT3 phosphorylation in macrophages shifting their activity towards a pro-angiogenic subtype (Dace et al. 2008) . Such an IL-10 mediated shift in macrophage subtype towards lower anti-angiogenic capacity is increased with age (Kelly et al. 2007) . We find that patients with neovascular AMD have plasma increase in both IL-6 and IL-10, which is particularly interesting as they have opposite function on the pro-angiogenetic STAT3 (Yasukawa et al. 2003) . In a recent study by Nakamura et al. underscoring the importance of IL-10 driven STAT3 signalling in macrophages in CNV formation in aged mice and in neovascular AMD, the proposed that a possible mechanism for the development of neovascular AMD may be through a low baseline SOCS3 in the aged . As SOCS3 requires IL-6 receptor activation to prevent downstream activation of STAT3 (Yasukawa et al. 2003) , a generally lower baseline SOCS3 in the aged would lead to a shift towards an IL-10 based activation of the macrophages and a higher angiogenic drive . Our findings therefore support a possible aetiological mechanism involving increased IL-10 and STAT3 activation in neovascular AMD.
Can we replace retinal fluorescein and indocyanine angiography with plasma biomarkers to differentiate neovascular AMD from PCV? The answer is no for the time being. Although the idea is interesting, neither this nor other studies have been able to identify blood biomarkers with a discriminate ability that is comparable to the current gold standard that is ICGA. However, approaches based on machine learning algorithms on a wide range of blood biomarker data may allow a more precise discrimination (Putin et al. 2016) .
It is important to acknowledge that an important limitation of this study is that associations do not equal causation, which requires experimental validation. In vitro RPE cell stimulation studies and CNV studies in rodents reviewed in this study provide a theoretical framework wherein it is plausible that inflammaging has a causative role for AMD development.
In this study, we conclude that plasma markers of inflammaging differentiate between PCV and neovascular AMD and that PCV is not associated with a specific inflammaging profile different from those in healthy controls. In contrast, patients with neovascular AMD partly present with features classically associated with inflammaging (increased CRP, IL-1b and IL-6) and partly present with features not classically associated with inflammaging (increased IL-10), which overall gives an angiogenesis-twisted inflammaging profile. Although elements of altered immunology may be present in PCV (Subhi et al. , 2018 , there is no strong evidence of an inflammaging-related aetiology. (Copenhagen, Denmark) . The funding bodies had no role in the design or conduct of this research. Author YS has previously received travel grant for conferences from Novartis and Bayer (not in relation to this work). Author MKN has previously received travel grant for conference from Novartis (not in relation to this work). Author CRM has previously received a travel grant from Bayer (not in relation to this work). Author AO has received grants from Novartis and Alcon, and speaker honoraria from Novartis and Bayer (not in relation to this work). Authors AS, MHS and TLS declare that no potential conflict of interests exists in relation to this work.
